Business
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CAMBRIDGE, Mass., April 17, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to a
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/44a13616385ce6d5b65ff1eb4a8057ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hb2oe4uWJR.wvTVKyj4dRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/44a13616385ce6d5b65ff1eb4a8057ae","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RZA8yG3Y6FDjSkhvwUotzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/44a13616385ce6d5b65ff1eb4a8057ae","width":1024,"height":512}},"lazy":false},{"type":"text","content":"$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., April 17, 2026--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to an aggregate of 2,222,223 shares of common stock and short-term Series J warrants to purchase up to an aggregate of 2,222,223 shares of common stock, at a purchase price of $2.25 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The Series I warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the short-term Series J warrants will expire eighteen months after the effective date of the Resale Registration Statement.","length":1147,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.","length":82,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering were approximately $5 million before deducting p...